Imperial College London

ProfessorRaoulCoombes

Faculty of MedicineDepartment of Surgery & Cancer

Professor of Medical Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2135c.coombes

 
 
//

Assistant

 

Mrs Suzy Ford +44 (0)20 7594 2135

 
//

Location

 

145ICTEM buildingHammersmith Campus

//

Summary

 

Summary

Professor Charles Coombes, Professor of Medical Oncology, Imperial College London. He is also Hon  Consultant Medical Oncologist, Imperial College Healthcare Trust.

From October 2010 Professor Coombes is Director of The Imperial CRUK Cancer Centre. He is also Chair  of The Imperial Cancer Research (UK) Centre Steering Committee and Theme leader for Cancer, Imperial College London.

He is engaged in developing novel methods for prediction of response to endocrine therapy in breast cancer and also carrying out research aimed at understanding the mechanisms of resistance to endocrine therapy and development of novel anti-cancer drugs.

In his capacity as Head of Division of Cancer until 30 September 2012, he was responsible for the running of the division, as well as the recruitment and retention of staff.  He is personally responsible for running the section of Cancer Cell Biology and has three CRUK Programme Grants and many other project and smaller grants.  This department currently has more than 280 scientific staff. The department has doubled in size over the past three years and now has and I4 Professors and twenty sections. 

His laboratory is focusing on elucidating molecular signals controlling aberrant growth of breast cancer cells with specific focus on the oestrogen receptor and allied cell signalling pathways. He works with scientists engaged in molecular target identification and chemists whose remit is to target specific signalling abnormalities to develop novel therapies for breast cancer.    He also runs a translational laboratory which focuses on detection of micrometastatic disease and application to the treatment of breast cancer.  He is Chairman of the International Collaborative Cancer Group. This is a multinational trial centre which is based within Imperial College focussing on phase II and phase III studies in breast cancer.

Invited Lectures

Many lectures each year: In the past two years I have been invited to give lectures in Australia, Taiwan, Japan, China, India, Brazil, Mexico, The USA, Holland, Belgium, Germany, Spain, Italy, Sweden, and Finland.

Publications

Journals

Saleem A, Searle GE, Kenny LM, et al., 2017, Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015), Ejnmmi Research, Vol:7, ISSN:2191-219X

Saleem A, Searle GE, Kenny LM, et al., 2017, Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015), Ejnmmi Research, Vol:7, ISSN:2191-219X

Palmieri C, Stein RC, Liu X, et al., 2017, IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients, Breast Cancer Research and Treatment, Vol:165, ISSN:0167-6806, Pages:343-353

Palmieri C, Szydlo R, Miller M, et al., 2017, IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer., Breast Cancer Res Treat

Morden JP, Alvarez I, Bertelli G, et al., 2017, Long-Term Follow-Up of the Intergroup Exemestane Study, Journal of Clinical Oncology, Vol:35, ISSN:0732-183X, Pages:2507-+

More Publications